Table 1.
The composition and basic characteristics of the iBodies.
| Conjugate (M n) | Target | No. of inhibitor moieties | No. of ATTO488 units | No. of biotin units | K i [nm] |
|---|---|---|---|---|---|
| iBody 1 (148 800)[a] | GCPII | 19 | 7 | 51 | 0.0043±0.0005 |
| iBody 2 (40 600)[a] | HIV‐1 protease | 6 | – | 7 | 7.9±0.5 |
| iBody 3 (42 100)[a] | Aspartic proteases | 7 | – | 9 | 18.9±0.2[b] |
| iBody 4 (135 800)[a] | His‐tag sequence | 12 | 7 | 46 | 3.5±0.1[c] |
| iBody 5 (108 100)[a] | – | – | 6 | 41 | – |
| iBody 6 (37 800)[a] | – | – | – | 8 | – |
[a] M n=number‐average molecular weight. For full molecular characteristics of the conjugates, see Table S2–S4 and Figure S8 in Supporting Information. [b] K i value was determined for wild‐type HIV‐1 protease. [c] For iBody 4, a dissociation constant K D is shown instead of an inhibition constant K i.